Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia 26Lymphoma, Non-Hodgkin 18Sarcoma 17Leukemia, Myeloid, Acute 16Hematologic Neoplasms 12Neuroblastoma 11Neoplasms 11Hodgkin Disease 11Myelodysplastic Syndromes 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia, Lymphocytic, Chronic, B-Cell 9Breast Neoplasms 9Burkitt Lymphoma 8Osteosarcoma 6Lymphoma, Large B-Cell, Diffuse 6Multiple Myeloma 5Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Rhabdoid Tumor 4Retinoblastoma 4Recurrence 4Neuroectodermal Tumors, Primitive, Peripheral 4Myeloproliferative Disorders 4Medulloblastoma 4Leukemia, Biphenotypic, Acute 4Leukemia, B-Cell 4Hematologic Diseases 4

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × Mesna × Clear all
NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡